EBP05

DRUG2 trials

Sponsors

Entera Bio Ltd.

Conditions

Fractures, BoneHypoparathyroidismOsteoporosisOther Disease

Phase 1

Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

CompletedNCT05965167

Entera Bio Ltd.Fractures, Bone, Hypoparathyroidism, Osteoporosis +1

Start: 2023-05-11End: 2026-02-08Updated: 2026-02-17

Phase 2

A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass

CompletedNCT04003467

Entera Bio Ltd.Osteoporosis

Start: 2019-06-30End: 2021-05-11Updated: 2021-06-28

Related Papers

SAT-758 Phase 1 Study Results Of EB612, A First-in-Class Oral PTH(1-34) Analog For The Treatment Of Hypoparathyroidism

Journal of the Endocrine Society2024-10-011 citations